Dominantly Inherited Alzheimer Network (DIAN)
Recruiting · NCT00869817 · Observational (researchers observe without assigning treatment) · Lead sponsor: Washington University School of Medicine
View the official record on ClinicalTrials.gov →What this trial is about
The purpose of this study is to identify potential biomarkers that may predict the development of Alzheimer's disease in people who carry an Alzheimer's mutation.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
Yes - healthy volunteers may be accepted
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Written informed consent obtained from participant and collateral source prior to any study-related procedures.
- Aged 18 (inclusive) or older and the child of an affected individual (clinically or by testing) in a pedigree with a known mutation for ADAD.
- Cognitively normal to very mild or mild cognitive impairment (CDR score range 0-1.0). Primary enrollment will focus on the recruitment of asymptomatic adult children who are more than 15 years younger than the estimated age of symptom onset. Enrollment of new participants with moderate cognitive impairment is allowed with the prior approval of the DIAN Coordinating Center.
- Has two persons who are not their full-blooded siblings who can serve as collateral sources for the study.
- Fluent in a language approved by the DIAN Coordinating Center at about the 6th grade level (international equivalent) or above.
Exclusion criteria
- Under age 18
- Medical or psychiatric illness that would interfere in completing initial and follow-up visits
- Requires nursing home level care
- Has no one who can serve as a study informant
Where it is running
26 locations listed across 8 US states.
- Mayo Clinic Jacksonville - Jacksonville, Florida, United States
- Indiana University-Indiana Alzheimer Disease Center - Indianapolis, Indiana, United States
- Brigham and Women's Hospital - Boston, Massachusetts, United States
- Washington University in St. Louis School of Medicine - St Louis, Missouri, United States
- Columbia University - New York, New York, United States
- University of Pittsburgh - Pittsburgh, Pennsylvania, United States
- Butler Hospital - Providence, Rhode Island, United States
- University of Washington - Seattle, Washington, United States
- Amsterdam UMC - Amsterdam, Netherlands
- Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia" (FLENI) Instituto de Investigaciones Neurológicas Raúl Correa - Buenos Aires, Argentina
- Institute of Neurology, Queen Square - London, United Kingdom
- German Center for Neurodegenerative Diseases (DZNE) Munich, and University Hospital Ludwig-Maximilians-Universitat (LMU) Munich - Munich, Germany
- Niigata University - Niigata, Japan
- Osaka City University - Osaka, Japan
- Tokyo University - Tokyo, Japan
- German Center for Neurodegenerative Diseases (DZNE) Tübingen and Hertie-Institute for Clinical Brain Research, University of Tübingen - Tübingen, Germany
- Hospital Clinic Barcelona - Barcelona, Catalonia, Spain
- Grupo Neurociencias de Antioquia - Medellín, Colombia, Colombia
- Instituto Nacional de Neurología y Neurocirugía "Manuel Velasco Suarez" - Mexico City, Mexico City, Mexico
- Neuroscience Research Australia - Sydney, New South Wales, Australia
- McGill University Research Centre for Studies in Aging - Verdun, Quebec, Canada
- Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia (FLENI) - Salta, Salta Province, Argentina
- Asan Medical Center - Seoul, Songpa-Gu, South Korea
- Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo - São Paulo, São Paulo, Brazil
- Mental Health Research Institute, University of Melbourne - Melbourne, Victoria, Australia
- Sir James McCusker Alzheimer's Disease Research Unit, Edith Cowan University - Perth, Western Australia, Australia